Advertisement

Dr Reddy''s inks pact with Gilead to manufacture COVID-19 drug

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: Dr Reddy''s Laboratories on Saturday said it has inked pact with US-based Gilead Sciences to manufacture and market Remdesivir - a potential treatment for COVID-19 - in 127 countries, including India.

As per the non-exclusive licensing agreement, Gilead will grant the Hyderabad-based drug maker the right to register and manufacture its investigational drug Remdesivir in 127 countries, Dr Reddy''s Laboratories said in a statement.

Advertisement

The company will receive technology transfer from Gilead for manufacturing of the drug, it added.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Dr Reddy''s would need to scale up manufacturing and obtain regulatory approval for marketing of this drug in respective countries, the company said.

Remdesivir, an investigational antiviral therapy developed by Gilead, has received Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19. PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST